Kyverna Therapeutics (KYTX) Non-Current Assets (2023 - 2026)
Kyverna Therapeutics' (KYTX) quarterly Non-Current Assets came in at $15.3 million in Q1 2026, up 17.64% YoY from $13.0 million in Q1 2025, and up 40.7% on a QoQ basis from $10.9 million in Q4 2025.
Kyverna Therapeutics (KYTX) Non-Current Assets (2023 - 2026) Analysis & Trends
Kyverna Therapeutics (KYTX) has 4 years of Non-Current Assets data on file, last reported at $15.3 million in Q1 2026.
- Quarterly Non-Current Assets rose 17.64% year-over-year to $15.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $50.6 million (down 8.3% YoY) and the FY2025 annual result came in at $10.9 million, down 22.58% from the prior year.
- Non-Current Assets grew to $15.3 million in Q1 2026, from $10.9 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $15.3 million in Q1 2026 to a low of $10.9 million in Q4 2025.
- A 4-year average of $13.5 million and a median of $13.9 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2025 — Non-Current Assets fell 22.58% — and 2026, when it gained 17.64%.
- Tracing KYTX's Non-Current Assets over 4 years: stood at $14.5 million in 2023, then dropped by 3.35% to $14.0 million in 2024, then retreated by 22.58% to $10.9 million in 2025, then jumped by 40.7% to $15.3 million in 2026.
- The last three Non-Current Assets figures came in at $15.3 million (Q1 2026), $10.9 million (Q4 2025), and $12.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Kyverna Therapeutics | 505.26 Mn | 505.26 Mn | - | 13.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.28 Mn |
| Mar 31, 2026 | 15.30 Mn |
| Dec 31, 2025 | 10.87 Mn |
| Sep 30, 2025 | 12.23 Mn |
| Jun 30, 2025 | 12.18 Mn |
| Mar 31, 2025 | 13.00 Mn |
| Dec 31, 2024 | 14.04 Mn |
| Sep 30, 2024 | 13.82 Mn |
| Jun 30, 2024 | 14.29 Mn |
| Mar 31, 2024 | 14.50 Mn |
| Dec 31, 2023 | 14.53 Mn |